InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,914.71
(
2.23%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: None

Saturday, 01/27/2007 4:21:05 PM

Saturday, January 27, 2007 4:21:05 PM

Post# of 4764
Research on MAB 806, an anti-EGFR antibody with distinct epitope specificity.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

Comments/Questions:

1. I find it interesting that MAB 806 and a cetuximab-like antibody have additive/synergistic effects.

2. What do we know about Imclone's human anti-EGFR? Compared to cetuximab, are there any differences in affinity and epitope specificty. I seem to recall in a presentation that it binds a similar (same?) epitope as Erbitux.

3. MAB 806 (or a humanized derivative) looks like an interesting molecule that industry may want to develop.

biophud
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up